EP Biocomposites Ltd (EPBIO) fair value: what the stock is really worth
As of Nov 3, 2026: fair value (intrinsic value) of EP Biocomposites Ltd stock ₹165, price ₹88.00, upside +88.0%, quality 63 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
50‑month range ₹84.00 – ₹346.95 · fair‑value band ₹92.87 – ₹224.71 · the ₹88.00 price screens below the ₹165.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow EP Biocomposites in your weekly email
Every Wednesday you see whether EP Biocomposites is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EP Biocomposites Ltd (EPBIO) currently trades at ₹88.00, while our model-based Fair Value estimate is ₹165.46, implying the stock looks roughly 47% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹227.87 per share, and 21 of the 24 models we run sit above the ₹88.00 price.
Bear case: the Asset-Based group reads lowest at ₹53.86, and 3 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹92.87 (bear) to ₹224.71 (bull), the price of ₹88.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Materials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
EP Biocomposites Ltd reported revenue of ₹136M in FY2026 versus ₹80.6M in FY2022, a compound +14.1%/yr. Reported net income was ₹14.6M in FY2026, compounding +15.9%/yr from FY2022.
Key figures
Market cap ₹148M (≈ $1.6M) Micro · P/E ratio 10.1 · P/S ratio 1.09 · EPS (TTM) ₹8.67 · Net margin 10.7% · Return on equity 12.9% · Return on assets (EBIT) 10.6% (5-year average) · Operating margin 20.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Materials peers we cover trades at −26% fair-value upside, at 88%, EPBIO screens cheaper than that median.
Fair Value models
Bear₹92.87Fair Value ₹165.46Bull₹224.71
Price ₹88.00 · Upside +88.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹5.27 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF₹150.15₹218.12₹401.1078
Growth DCF₹141.71₹228.54₹376.2377
Owner Earnings₹86.46₹169.02₹313.9073
All 24 models by family
DCF Models
FCF DCF₹150.15₹218.12₹401.1078
Owner Earnings₹86.46₹169.02₹313.9073
5Y Revenue Exit₹110.50₹184.93₹329.9270
5Y EBITDA Exit₹115.76₹196.12₹343.3872
5Y P/E Exit₹122.43₹235.01₹378.5569
10Y Revenue Exit₹120.27₹216.24₹307.9866
10Y EBITDA Exit₹126.14₹225.05₹398.3366
10Y P/E Exit₹130.21₹236.20₹413.9261
Earnings-Based
Graham-Dodd₹58.97₹411.27₹577.1663
Lynch FV₹129.07₹184.38₹239.6961
PEG = 1.0₹129.07₹184.38₹239.6957
EPV₹74.15₹82.95₹90.1171
Multiples
P/E Multiple₹110.58₹147.43₹184.2963
P/S Multiple₹91.26₹121.68₹152.0958
P/B Multiple₹160.17₹213.57₹266.9655
EV/EBIT₹131.94₹176.40₹220.8666
EV/EBITDA₹98.34₹131.60₹164.8667
EV/Revenue₹83.73₹120.24₹156.7453
Asset-Based
NCAV (Graham)₹35.55₹53.86₹67.3354
Growth DCF
Growth DCF₹141.71₹228.54₹376.2377
Rev-Margin DCF₹110.50₹202.16₹340.4770
Economic Profit
Residual Income₹60.05₹66.54₹81.3571
ROIC Compounder₹75.86₹97.10₹114.0872
Growth Earnings
Growth-Adj P/E₹159.51₹227.87₹296.2367
The fair value above starts from this blend and is adjusted for a cyclical peak year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.8%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+20.1%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 16%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −6.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Construction Materials” was too small, so the broader sector is used.)Materials · 3364 stocks
Beats the sector median on 12/13 measures
Overall it ranks above its sector peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside+88.0% · Top 25%
Profitability
Return on equity (12 months)12.9% · Top 25%
Return on assets7.8% · Top 25%
Net margin (12 months)10.7% · Above median
Operating margin (12 months)20.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)25.8% · Above median
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Materials median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is EP Biocomposites Ltd (EPBIO) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ₹165.46 versus a price of ₹88.00, about +88% upside (undervalued).
What is the fair value of EPBIO?
Our model-based fair value for EP Biocomposites Ltd is ₹165.46 (as of Nov 7, 2026), built from audited fundamentals. The current price: ₹88.00.
What is the quality score of EPBIO?
EP Biocomposites Ltd has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EP Biocomposites Ltd (EPBIO)?
Our model-based price target is the fair value of ₹165.46 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario ₹92.87, optimistic scenario ₹224.71. It is a calculation from audited fundamentals, not an analyst target.
What is the EP Biocomposites Ltd stock forecast for 2026?
Our models put fair value at ₹165.46, about +88% upside versus a price of ₹88.00 (undervalued). Cautious scenario ₹92.87, optimistic scenario ₹224.71. The calculation is refreshed regularly with new filings.
What is the revenue of EP Biocomposites Ltd (EPBIO)?
EP Biocomposites Ltd reported trailing-twelve-month revenue of about ₹136M (latest available figure, as of Nov 7, 2026).
What growth is priced into EP Biocomposites Ltd (EPBIO)?
For today's price to be fair in a discounted-cash-flow model, EP Biocomposites Ltd would have to grow free cash flow by -2.1 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of EPBIO use?
Our models discount EP Biocomposites Ltd at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EP Biocomposites Ltd that is -2.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has EP Biocomposites Ltd (EPBIO) delivered so far?
Over the past 5 years revenue at EP Biocomposites Ltd grew +35.9 % a year. The price currently implies free-cash-flow growth of -2.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of EP Biocomposites Ltd (EPBIO)?
The free-cash-flow yield on the price is 12.74 %: that much free cash flow EP Biocomposites Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EP Biocomposites Ltd (EPBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EP Biocomposites Ltd it is ₹165.46 per share (as of Nov 7, 2026), against a price of ₹88.00. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is EP Biocomposites Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, EPBIO trades below its calculated fair value: price ₹88.00, fair value ₹165.46, a gap of about +88% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPBIO?
No. The price is what the market pays today (₹88.00); the fair value is what the company's own numbers justify (₹165.46). For EP Biocomposites Ltd the two are ₹77.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is EP Biocomposites Ltd worth?
The market values EP Biocomposites Ltd at about ₹148M (market capitalisation, as of Nov 7, 2026). Per share that is ₹88.00; our models calculate a fair value of ₹165.46 per share.
What do the bullish and bearish scenarios say about EPBIO?
Our models span a range for EP Biocomposites Ltd: cautious scenario ₹92.87, base ₹165.46, optimistic ₹224.71 per share (as of Nov 7, 2026, price ₹88.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EPBIO?
EP Biocomposites Ltd trades at a price-to-earnings ratio of 10.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹165.46 is built from several models across several years. Other multiples: P/B 1.2, P/S 1.1, EV/EBITDA 6.3.
How solid is the balance sheet of EP Biocomposites Ltd (EPBIO)?
Balance-sheet figures for EP Biocomposites Ltd (as of Nov 7, 2026): return on equity 12.9%, debt of 0.16 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is EPBIO from its 52-week high?
EP Biocomposites Ltd trades at ₹88.00, about 31% below its 52-week high of ₹128.00 and 5% above the low of ₹84.00 (as of Nov 3, 2026). Distance from the high says nothing about value: that is what the fair value of ₹165.46 is for.
Which stocks are comparable to EP Biocomposites Ltd?
From the same area (Materials) we also value CHP, Seosan Corporation, DHABRIYA, MARBLE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EP Biocomposites Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ₹88.00, calculated fair value ₹165.46 (+88%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EPBIO calculated?
We run EP Biocomposites Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹165.46 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. EP Biocomposites Ltd currently trades 47% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EP Biocomposites Ltd (EPBIO)?
The closing price on Nov 3, 2026 was ₹88.00. Our model-based fair value is ₹165.46, about +88% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EP Biocomposites Ltd right now?
The price is below even our cautious bear case (₹92.87). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (₹92.87 to ₹224.71) leaves room in how you read the outcome.
Key figures of EP Biocomposites Ltd
How large is the market capitalisation of EP Biocomposites Ltd (EPBIO)?
The market capitalisation of EP Biocomposites Ltd is ₹148M (≈ $1.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EP Biocomposites Ltd (EPBIO)?
The price-to-sales ratio of EP Biocomposites Ltd is 1.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EP Biocomposites Ltd (EPBIO)?
Earnings per share at EP Biocomposites Ltd are ₹8.67 (price ÷ EPS = P/E 10.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EP Biocomposites Ltd (EPBIO)?
The net margin of EP Biocomposites Ltd is 10.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EP Biocomposites Ltd (EPBIO)?
The return on equity (ROE) of EP Biocomposites Ltd is 12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EP Biocomposites Ltd (EPBIO)?
On an EBIT basis the return on assets of EP Biocomposites Ltd is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EP Biocomposites Ltd (EPBIO)?
The operating margin of EP Biocomposites Ltd is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EP Biocomposites Ltd (EPBIO)?
Revenue at EP Biocomposites Ltd is growing +25.8% versus a year earlier (3y avg +24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EP Biocomposites Ltd (EPBIO)?
Earnings per share at EP Biocomposites Ltd are growing +64.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EP Biocomposites Ltd (EPBIO) carry?
The net debt of EP Biocomposites Ltd is ₹2.4M (fiscal year 2026, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EP Biocomposites Ltd in the live analysis
One click puts EP Biocomposites Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026